MC

456.9

-1.13%↓

BNP

78.43

-0.09%↓

DB1.DE

254.8

-0.7%↓

NDA.FI

12.78

-0.16%↓

DIM

168.85

-1.14%↓

MC

456.9

-1.13%↓

BNP

78.43

-0.09%↓

DB1.DE

254.8

-0.7%↓

NDA.FI

12.78

-0.16%↓

DIM

168.85

-1.14%↓

MC

456.9

-1.13%↓

BNP

78.43

-0.09%↓

DB1.DE

254.8

-0.7%↓

NDA.FI

12.78

-0.16%↓

DIM

168.85

-1.14%↓

MC

456.9

-1.13%↓

BNP

78.43

-0.09%↓

DB1.DE

254.8

-0.7%↓

NDA.FI

12.78

-0.16%↓

DIM

168.85

-1.14%↓

MC

456.9

-1.13%↓

BNP

78.43

-0.09%↓

DB1.DE

254.8

-0.7%↓

NDA.FI

12.78

-0.16%↓

DIM

168.85

-1.14%↓

Search

BRANICS Group AG

Cerrado

1.91

Resumen

Variación precio

24h

Actual

Mínimo

1.9

Máximo

1.95

Métricas clave

By Trading Economics

Ingresos

171M

-15M

Ventas

-6.3M

54M

BPA

0.21

Margen de beneficio

-27.726

Empleados

310

EBITDA

-11M

34M

Recomendaciones

By TipRanks

Recomendaciones

Vender

Estimación a 12 meses

-15.84% downside

Dividendos

By Dow Jones

Próximas Ganancias

27 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

334M

Apertura anterior

1.91

Cierre anterior

1.91

BRANICS Group AG Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

4 ago 2025, 21:42 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 ago 2025, 21:21 UTC

Ganancias
Principales Movimientos del Mercado

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 ago 2025, 20:45 UTC

Ganancias

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 ago 2025, 19:15 UTC

Principales Movimientos del Mercado

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 ago 2025, 23:41 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 ago 2025, 23:41 UTC

Charlas de Mercado

Nikkei May Rise on Fed Stimulus Hopes

4 ago 2025, 23:28 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

4 ago 2025, 23:28 UTC

Charlas de Mercado

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 ago 2025, 21:30 UTC

Ganancias

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 ago 2025, 21:21 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 ago 2025, 21:18 UTC

Ganancias

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 ago 2025, 20:25 UTC

Charlas de Mercado

India Hits Back Over Russian Oil Purchases -- Market Talk

4 ago 2025, 20:25 UTC

Ganancias

Transocean 2Q Loss $938M >RIG

4 ago 2025, 20:25 UTC

Ganancias

Transocean 2Q Loss/Shr $1.06 >RIG

4 ago 2025, 20:18 UTC

Ganancias

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 ago 2025, 20:15 UTC

Ganancias

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 ago 2025, 20:14 UTC

Ganancias

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 ago 2025, 20:14 UTC

Ganancias

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 ago 2025, 20:14 UTC

Ganancias

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 ago 2025, 20:13 UTC

Ganancias

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 ago 2025, 20:09 UTC

Ganancias

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 ago 2025, 20:06 UTC

Ganancias

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 ago 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 ago 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 ago 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 ago 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 ago 2025, 19:41 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 ago 2025, 19:28 UTC

Charlas de Mercado

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 ago 2025, 19:07 UTC

Charlas de Mercado

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 ago 2025, 18:27 UTC

Charlas de Mercado

Gold Climbs on Rate Cut Speculation -- Market Talk

Comparación entre iguales

Cambio de precio

BRANICS Group AG Esperado

Precio Objetivo

By TipRanks

-15.84% caída

Estimación a 12 meses

Media 1.7 EUR  -15.84%

Máximo 1.7 EUR

Mínimo 1.7 EUR

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BRANICS Group AG Dist en los últimos 3 meses.

Consenso

By TipRanks

Vender

1 ratings

0

Comprar

0

Mantener

1

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de BRANICS Group AG

Branicks Group AG (formerly DIC Asset AG) is Germany's leading listed specialist for office and logistics real estate with 25 years of experience on the real estate market and with access to a broad-based network of investors. Our business is based on a regional and inter-regional real estate platform with nine offices on the ground in all major German markets (with VIB Vermögen AG included). We currently manage a total of 358 assets with a combined market value of EUR 14.2 billion on site, always close to our properties and their occupiers. The Commercial Portfolio segment comprises real estate held for our own account. Here, we generate steady cash flows from stable rent revenues on long-term leases while also optimising the value of our portfolio assets through active management, and realising gains from sales. In the Institutional Business segment, we earn recurrent fees from real estate services we provide to national and international institutional investors by structuring and managing investment products that return attractive dividend yields.